新型序貫療法對難治性幽門螺旋菌感染的療效分析  

An innovative sequential regimen for the eradication of refractory helicobacter pylori infection

作　　者：余漢濠 張進文 鄭展宏 徐義祥 陳春燕 YU Hon Ho;ZHANG Jin Wen;CHINg Chin Wang;CHOI I Cheong;CHAN Chun Yan(Department of Digestive disease,Kiang Wu Hospital,Macao,China)

机构地区：[1]澳門鏡湖醫院消化内科,中國

出　　处：《镜湖医学》2020年第1期11-14,10,共5页MEDICAL JOURNAL OF KIANG WU

摘　　要：目的研究含N-乙酰半胱氨酸的21天序貫療法在難治性幽門螺旋菌感染(Helicobacter pylori,HP)的臨床應用價值。方法連續性收集HP治療失敗患者,包括初治失敗及復治失敗者,給予含N-乙酰半胱氨酸的21天序貫療法治療,所有受試者於療程結束4週後行復檢(13C呼氣試驗檢測或大便HP抗原檢測)。結果85名難治性HP感染患者經過21天序貫治療後的治癒率為77.6%(intention to treat,ITT)及90.4%(Per Protocol,PP),其中三次或以上復治失敗的挽救清除率可達80.9%(ITT)及94.4%(PP),未發現性別,年齡或復治次數對清除率有影響(P>0.05)。結論含N-乙酰半胱氨酸的21天序貫方案在難治性幽門螺桿菌感染的治療中有理想效果。Objective To evaluate the efficacy of 21 days sequential regimen containing N-acetyl cysteine in the eradication of refractory Helicobacter pylori infection.Methods This was a non randomized single center study,patients were included consecutively,in whom standard anti HP regimen or second line regimen had failed.21 days sequential regimen was prescribed.Eradication rate was confirmed by 13C-urea breath test or HP antigen stool test.Results Totally 85 patients were included and eradication rate was 77.6%in intention to treat(ITT)analysis and 90.4%in Per Protocol(PP)analysis.In sub-analysis,eradication rate of 80.1%(ITT)and 94.4%(PP)was gained respectively in patients who at least failed to two previous regimens.Variables studied,including gender,age and failure numbers,showed no association with the eradication rate(P>0.05).Conclusion 21 days sequential regimen including N-acetyl cysteine is useful in the eradication of refractory helicobacter pylori infection.

关 键 词：N-乙酰半胱氨酸 難治性 幽門螺桿菌 挽救治療 多西環素 

分 类 号：R57[医药卫生—消化系统]